Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Shilpa Medicare Ltd - 530549 - Outcome Of Board Meeting - Reg. Reg 33: Financial Results - Reg. Ref: Regulation 30 And Regulation 33 Of The SEBI (LODR) Regulations, 2015; Scrip Code: BSE - 530549/ Stock Symbol: NSE - SHILPAMED

 With reference to the captioned subject please be noted that the board of directors at their meeting held today 31.05.2021, to inter alia considered and approved the following. 1. Audited Standalone and Consolidated Financial Statements for the Financial Year ended 31st March, 2021. 2. Auditor's Report for the Financial Year ended 31st March, 2021. 3. To recommend the Dividend @ 110% (i.e. Rs.1.10 per every equity share of face value of Rs.1) for the Financial Year 2020-21 subject to the approval of shareholders at the ensuing Annual General Meeting. 4. Appointment of Mr. Alpesh Dalal as Chief Financial Officer of the Company. Brief profile is enclosed as an annexure The board Meeting Started at 11:30 am and Concluded at 03:10 pm. o
31-05-2021
Bigul

SHILPA MEDICARE LTD. - 530549 - Intimation U/R 30 Of The SEBI(LODR) Regulations- Reg

 We hereby inform that the Shilpa Medicare Ltd's Finished Dosage Formulation Facility (Sterile and Non-sterile) located at S-20 to S-26, Pharmaceutical Formulations SEZ, TSIIC, Jadcherla, Telangana State, India has been issued GMP certification by Ministry of Industry and Trade of the Russian Federation for the GMP inspection held from 22-02-2021 to 26-02-2021. There were No Critical, Major and Minor observations found during GMP inspection process.
28-05-2021
Bigul

Shilpa Medicare Ltd - 530549 - Corporate Action-Board to consider Dividend

 We inform you that the Board may inter-alia, consider the proposal of recommendation of dividend, if any, for the financial year 2020-21 at their meeting to be held on Monday, the 31st Day of May, 2021.
25-05-2021
Bigul

SHILPA MEDICARE LTD. - 530549 - Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.

 SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/05/2021 ,inter alia, to consider and approve Approval of the Audited Standalone and Consolidated Financial Results of the Company for the Fourth Quarter and the Financial Year ended 31st March, 2021.
24-05-2021

Shilpa Medicare zooms 26% in 2 days after DRL vaccine deal

 In five consecutive sessions, the counter has surged 30 per cent.
18-05-2021

Covid-19: Shilpa Medicare ties up with Dr Reddy's for Sputnik V

 Targeted production of dual vector vaccine for first 12 months is 50 million doses
17-05-2021
Bigul

SHILPA MEDICARE LTD. - 530549 - Shilpa Medicare Limited Ties Up With Dr. Reddy'S Laboratories Limited For Production Of Sputnik V Vaccine

 This is to inform you that the Company, via its wholly owned subsidiary Shilpa Biologicals Private Limited (SBPL), has entered into a 3 year Definitive Agreement with Dr. Reddy's Laboratories Limited (DRL) for production-supply of the Sputnik V vaccine from its integrated biologics R&D; cum manufacturing center at Dharwad, Karnataka
17-05-2021
Bigul

SHILPA MEDICARE LTD. - 530549 - NON APPLICABILITY OF LARGE CORPORATE

 We hereby confirm that Shilpa Medicare Limited does not fall under the criteria of ''Large Corporate'' as of March 31, 2021 as per the applicability criteria mentioned under the aforesaid SEBI Circular. This is for your information and records.
14-05-2021
Bigul

SHILPA MEDICARE LTD. - 530549 - Intimation U/R 30 Of The SEBI(LODR) Regulations- Reg

 Shilpa Pharma, Inc. a U.S operating company of Shilpa Medicare Limited ('Shilpa') filed patent infringement lawsuit against Novartis Pharmaceutical Corporation in the United States District court for the district of Delaware seeking relief for the infringement of the US Patent No. 9,266,816 entitled 'Fingolimod Polymorph and Their Processes'.
26-04-2021
Bigul

Shilpa Medicare Ltd - 530549 - Compliance Certificate For Half Year Ended 31St March, 2021

 Dear Sir/ Madam With reference to the subject cited above, please find attached herewith the Compliance Certificate under Regulation 40(9) of SEBI (LODR) Regulations, 2015, issued by the Practicing Company Secretary M/s P.S Rao & Associates
17-04-2021
Next Page
Close

Let's Open Free Demat Account